These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 28509395

  • 1. DA-EPOCH-R for post-transplant lymphoproliferative disorders.
    DeStefano CB, Malkovska V, Rafei H, Shenoy A, Fitzpatrick K, Aggarwal A, Catlett JP.
    Eur J Haematol; 2017 Sep; 99(3):283-285. PubMed ID: 28509395
    [Abstract] [Full Text] [Related]

  • 2. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S, German PTLD Study Group, European PTLD Network.
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [Abstract] [Full Text] [Related]

  • 3. Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant.
    Burns DM, Clesham K, Hodgson YA, Fredrick L, Haughton J, Lannon M, Hussein H, Shin JS, Hollows RJ, Robinson L, Byrne C, McNamara C, Vydianath B, Lennard AL, Fields P, Johnson R, Wright J, Fox CP, Cwynarski K, Chaganti S.
    Transplantation; 2020 Dec; 104(12):2582-2590. PubMed ID: 33104308
    [Abstract] [Full Text] [Related]

  • 4. Treatment of PTLD with rituximab or chemotherapy.
    Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, Olthoff KM, Schuster SJ, Nasta SD, Stadtmauer EA, Tsai DE.
    Am J Transplant; 2006 Mar; 6(3):569-76. PubMed ID: 16468968
    [Abstract] [Full Text] [Related]

  • 5. Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.
    Podoltsev N, Zhang B, Yao X, Bustillo I, Deng Y, Cooper DL.
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):716-20. PubMed ID: 24035715
    [Abstract] [Full Text] [Related]

  • 6. Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective.
    Rubinstein JD, Shah R, Breese EH, Burns KC, Mangino JL, Norris RE, Lee L, Mizukawa B, O'Brien MM, Phillips CL, Perentesis JP, Pommert L, Absalon MJ.
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29126. PubMed ID: 34019326
    [Abstract] [Full Text] [Related]

  • 7. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H, Reinke P, Neuhaus R, Lehmkuhl H, Oertel S, Atta J, Planker M, Gärtner B, Lenze D, Anagnostopoulos I, Riess H, Trappe RU.
    Cancer; 2012 Oct 01; 118(19):4715-24. PubMed ID: 22392525
    [Abstract] [Full Text] [Related]

  • 8. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
    Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S.
    J Clin Oncol; 2017 Feb 10; 35(5):536-543. PubMed ID: 27992268
    [Abstract] [Full Text] [Related]

  • 9. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
    Martínez-Calle N, Alfonso A, Rifón J, Herrero I, Errasti P, Rábago G, Merino J, Panizo Á, Pardo J, Prósper F, García-Muñoz R, Lecumberri R, Panizo C.
    Eur J Haematol; 2017 Jan 10; 98(1):38-43. PubMed ID: 27232286
    [Abstract] [Full Text] [Related]

  • 10. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
    Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Bachy E, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, Trappe RU.
    Transplantation; 2018 Nov 10; 102(11):1914-1923. PubMed ID: 29757894
    [Abstract] [Full Text] [Related]

  • 11. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Dörken B, Oertel S.
    Transplantation; 2007 Apr 15; 83(7):912-8. PubMed ID: 17460562
    [Abstract] [Full Text] [Related]

  • 12. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
    Kuriyama T, Kawano N, Yamashita K, Ueda A.
    J Clin Exp Hematop; 2014 Apr 15; 54(2):149-53. PubMed ID: 25318948
    [Abstract] [Full Text] [Related]

  • 13. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S, Sekiguchi S, Kawagishi N, Akamatsu Y, Satoh K, Takeda I, Fukushima D, Kobayashi Y, Tokodai K, Fujimori K, Satomi S.
    Transplant Proc; 2011 Nov 15; 43(9):3299-301. PubMed ID: 22099782
    [Abstract] [Full Text] [Related]

  • 14. Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases.
    Patel H, Vogl DT, Aqui N, Shaked A, Olthoff K, Markmann J, Reddy R, Stadtmauer EA, Schuster S, Tsai DE.
    Leuk Lymphoma; 2007 May 15; 48(5):885-91. PubMed ID: 17487731
    [Abstract] [Full Text] [Related]

  • 15. Modified cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy for posttransplantation lymphoproliferative disease in pediatric patients undergoing solid organ transplantation.
    Suryanarayan K, Natkunam Y, Berry G, Bangs CD, Cherry A, Dahl G.
    J Pediatr Hematol Oncol; 2001 Oct 15; 23(7):452-5. PubMed ID: 11878581
    [Abstract] [Full Text] [Related]

  • 16. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, García-Marco JA, Castellví J, Montes-Moreno S, Batlle A, de Villambrosia SG, Carnicero F, Ferrando-Lamana L, Piris MA, Lopez A.
    Br J Haematol; 2015 Apr 15; 169(2):188-98. PubMed ID: 25521006
    [Abstract] [Full Text] [Related]

  • 17. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.
    Fohrer C, Caillard S, Koumarianou A, Ellero B, Woehl-Jaeglé ML, Meyer C, Epailly E, Chenard MP, Lioure B, Natarajan-Ame S, Maloisel F, Lutun P, Kessler R, Moulin B, Bergerat JP, Wolf P, Herbrecht R.
    Br J Haematol; 2006 Sep 15; 134(6):602-12. PubMed ID: 16889621
    [Abstract] [Full Text] [Related]

  • 18. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC.
    J Clin Oncol; 2005 Sep 20; 23(27):6481-8. PubMed ID: 16170157
    [Abstract] [Full Text] [Related]

  • 19. EBV and posttransplantation lymphoproliferative disease: what to do?
    Zimmermann H, Trappe RU.
    Hematology Am Soc Hematol Educ Program; 2013 Sep 20; 2013():95-102. PubMed ID: 24319169
    [Abstract] [Full Text] [Related]

  • 20. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.
    Choquet S, Trappe R, Leblond V, Jäger U, Davi F, Oertel S.
    Haematologica; 2007 Feb 20; 92(2):273-4. PubMed ID: 17296588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.